Bayer has secured a significant victory in the long-running Roundup cancer litigation after a Missouri jury rejected allegations that its weedkiller caused cancer in three women. The October 29, 2026, verdict comes as the German company awaits a separate court decision on a proposed $7.25 billion settlement intended to resolve thousands of similar claims.
The case was closely watched because it was the first Roundup trial since the U.S. Supreme Court restricted a major legal argument previously used against Bayer’s Monsanto subsidiary.
Missouri Jury Rules in Monsanto’s Favor
A jury in St. Louis County unanimously sided with Monsanto in a lawsuit brought by Theresa Aretino, Cynthia Fernandez and Betty Larkin. The women filed their claims in 2020, alleging that repeated exposure to Roundup contributed to their non-Hodgkin lymphoma, a form of blood cancer. Their case proceeded on allegations of defective product design, fraud, and negligence.
The jury rejected those claims. The verdict resolves this particular trial in Monsanto’s favor, but does not settle the wider scientific dispute or automatically dismiss other lawsuits. Bayer welcomed the decision, arguing that it demonstrates the challenges plaintiffs face in proving remaining claims against the company.
Why the Supreme Court Ruling Matters
In June 2026, the U.S. Supreme Court ruled in Monsanto v. Durnell that certain state-law claims based on missing cancer warnings were preempted by federal pesticide-labeling requirements.
Previously, many Roundup plaintiffs argued that Monsanto should have warned consumers about potential cancer risks. The decision narrowed that pathway where the Environmental Protection Agency had approved labeling without such a warning. That left lawyers pursuing other theories, including whether the product itself was defectively designed or sold negligently.
The Missouri verdict is therefore important beyond the three plaintiffs. It offers an early indication of how a jury may evaluate those alternative arguments, although a jury’s decision in one case does not establish a binding rule for every future case.
$7.25 Billion Roundup Settlement Still Pending
Bayer continues to face approximately 65,000 Roundup-related claims in U.S. state and federal courts. To limit its long-term legal exposure, Monsanto has proposed a settlement worth up to $7.25 billion. The plan would create a compensation process for eligible current and future claimants who allege Roundup exposure and a diagnosis of non-Hodgkin lymphoma.
Payments would be funded over as many as 21 years, subject to the agreement’s terms. A Missouri judge held a final approval hearing on September 14, 2026, but a decision remained pending as of October 31. The settlement is separate from the St. Louis jury case, and the three plaintiffs in that trial are not participating in the proposed agreement.
Glyphosate Safety Remains Disputed
Roundup contains glyphosate, an herbicide used to control weeds. Bayer maintains that extensive scientific research supports the safety of glyphosate when used as directed and denies that the product causes cancer.
The U.S. Environmental Protection Agency has not required a cancer warning on Roundup labels and is reviewing glyphosate’s safety. However, the International Agency for Research on Cancer classified glyphosate as probably carcinogenic to humans in 2015. That difference in scientific and regulatory assessments remains central to public debate and ongoing litigation.
What Happens Next?
The next major development will be the Missouri court’s decision on the proposed settlement. Approval could establish a path for resolving many claims, although challenges, exclusions and additional legal proceedings may remain.
For now, Bayer’s courtroom victory strengthens its defense strategy but does not end the Roundup litigation. Tens of thousands of cases and the unsettled compensation plan mean the company’s legal exposure remains a significant issue.
